Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.51 |
| ▸ | BMP1 | P13497 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519402 | 0.90 | ACHE (0.57) | AOC3ACHEMTNR1AMTNR1BTAAR1 | |
| SCHEMBL5515766 | 0.87 | OPRM1 (0.53) | AOC3MTNR1AMTNR1BBMP1 | |
| SCHEMBL3648866 | 0.85 | ALOX5 (0.58) | AOC3BMP1PTGESALOX5 | |
| SCHEMBL5513402 | 0.83 | AOC3 (0.50) | AOC3ACHEMTNR1AMTNR1BBMP1 | |
| SCHEMBL6184511 | 0.83 | KMT2A (0.62) | AOC3BMP1TSPOCHRM1CHRM3 | |
| SCHEMBL6715386 | 0.82 | NPC1 (0.61) | AOC3ACHEPTGESALOX5CHRM1 | |
| SCHEMBL11225170 | 0.82 | CHRM5 (0.60) | ACHEMTNR1AMTNR1BTSPOALOX5 | |
| SCHEMBL6715335 | 0.79 | PTGES (0.60) | AOC3ACHEMTNR1AMTNR1BPTGES | |
| SCHEMBL6716683 | 0.79 | ALOX5 (0.54) | AOC3MTNR1AMTNR1BPTGESALOX5 | |
| SCHEMBL10648377 | 0.79 | AOC3 (0.57) | AOC3ACHEMTNR1AMTNR1BBMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256201-B2 | Selective estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | disclosed |
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1341765-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046164-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ESR2, ESRRA, ESRRB | AOC3 3606/4885ACHE 1274/4885MTNR1A 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.